Cross talk between stimulated NF-κB and the tumor suppressor p53
暂无分享,去创建一个
D Saur | D. Saur | R. Schmid | F. Weih | G. Schneider | T. Wagner | T. Heinzel | O. Krämer | M. Wieczorek | R M Schmid | A. Henrich | G. Greiner | V. Wolf | Á. Lovas | S. Reichardt | A. Werder | O H Krämer | F Weih | G Schneider | A Henrich | G Greiner | V Wolf | A Lovas | M Wieczorek | T Wagner | S Reichardt | A von Werder | T Heinzel | Rm Schmid | Sigrid Reichardt | Martin Wieczorek
[1] B. Nayak,et al. Stabilization of p53 and transactivation of its target genes in response to replication blockade , 2002, Oncogene.
[2] A. Nakagawara,et al. ATM-dependent nuclear accumulation of IKK-α plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin , 2008, Oncogene.
[3] David F. Kashatus,et al. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. , 2006, Genes & development.
[4] G. Wahl,et al. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. , 2002, Cancer cell.
[5] S. Miyamoto,et al. Induction of a pro‐apoptotic ATM–NF‐κB pathway and its repression by ATR in response to replication stress , 2008, The EMBO journal.
[6] J. Brüning,et al. Riboflavin kinase couples TNF receptor 1 to NADPH oxidase , 2009, Nature.
[7] S. Lowe,et al. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. , 1993, Genes & development.
[8] R. Nussinov,et al. Protein-protein interaction networks: how can a hub protein bind so many different partners? , 2009, Trends in biochemical sciences.
[9] A. Berns,et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.
[10] M. Schmitz,et al. Autoregulatory feedback loops terminating the NF-kappaB response. , 2009, Trends in biochemical sciences.
[11] W. Greene,et al. p53 Induces NF-κB Activation by an IκB Kinase-independent Mechanism Involving Phosphorylation of p65 by Ribosomal S6 Kinase 1* , 2004, Journal of Biological Chemistry.
[12] M. Hung,et al. Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. , 2007, Molecular cell.
[13] O. Krämer. HDAC2: a critical factor in health and disease. , 2009, Trends in pharmacological sciences.
[14] Stephanie Spange,et al. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. , 2009, The international journal of biochemistry & cell biology.
[15] Vinay Tergaonkar,et al. NFκB pathway: A good signaling paradigm and therapeutic target , 2006 .
[16] Myriam Alcalay,et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells , 2009, Nature.
[17] Z. Cheng,et al. Cell fate decision mediated by p53 pulses , 2009, Proceedings of the National Academy of Sciences.
[18] G. Wahl,et al. p53 stabilization is decreased upon NFκB activation , 2002 .
[19] R. Stauber,et al. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis , 2008, Oncogene.
[20] F. Weih,et al. RelB is required for Peyer's patch development: differential regulation of p52–RelB by lymphotoxin and TNF , 2003, The EMBO journal.
[21] S. Gerondakis,et al. The Nuclear Factor-κB and p53 Pathways Function Independently in Primary Cells and Transformed Fibroblasts Responding to Genotoxic Damage , 2008, Molecular Cancer Research.
[22] Manuel Serrano,et al. The common biology of cancer and ageing , 2007, Nature.
[23] Karen H. Vousden,et al. p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.
[24] Jiandong Chen,et al. Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53* , 2002, The Journal of Biological Chemistry.
[25] N. Perkins,et al. Transcriptional cross talk between NF-kappaB and p53. , 1999, Molecular and cellular biology.
[26] K. Vousden,et al. Role of NF-kappaB in p53-mediated programmed cell death. , 2000, Nature.
[27] C. Prives,et al. p53 accumulates but is functionally impaired when DNA synthesis is blocked. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[28] I. Petersen,et al. Nuclear export is essential for the tumor‐promoting activity of survivin , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[29] V. Rotter,et al. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. , 2007, Cancer research.
[30] M. Karin. Nuclear factor-κB in cancer development and progression , 2006, Nature.
[31] N. Perkins,et al. Regulation of p53 tumour suppressor target gene expression by the p52 NF‐κB subunit , 2006, The EMBO journal.
[32] N. Perkins,et al. Transcriptional Cross Talk between NF-κB and p53 , 1999, Molecular and Cellular Biology.
[33] Michael B Yaffe,et al. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.
[34] J. Tschopp,et al. Signals from within: the DNA-damage-induced NF-kappaB response. , 2006, Cell death and differentiation.
[35] N. Mukaida,et al. IFN-γ Protects Cerulein-Induced Acute Pancreatitis by Repressing NF-κB Activation1 , 2007, The Journal of Immunology.
[36] D. Saur,et al. IKKα controls p52/RelB at the skp2 gene promoter to regulate G1‐ to S‐phase progression , 2006, The EMBO journal.
[37] M. Scian,et al. Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression , 2005, Molecular and Cellular Biology.
[38] L. O’Neill,et al. Diversity and regulation in the NF-kappaB system. , 2007, Trends in biochemical sciences.
[39] M. Karin. Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.
[40] R. Stauber,et al. Acetylation of Stat1 modulates NF-kappaB activity. , 2006, Genes & development.
[41] C. Subramanian,et al. Signaling from p53 to NF-kappaB determines the chemotherapy responsiveness of neuroblastoma. , 2006, Neoplasia.
[42] R. Hruban,et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.
[43] K. Roemer,et al. Inhibition of p53 protects liver tissue against endotoxin‐induced apoptotic and necrotic cell death , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[44] C. Schoch,et al. Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia , 2005, Cancer.
[45] M. Scian,et al. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. , 2005, Molecular and cellular biology.
[46] Rinat Abramovitch,et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.
[47] D. Saur,et al. A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors , 2008, Proceedings of the National Academy of Sciences.
[48] C. Arrowsmith,et al. p53 Transcriptional Activation Domain: A Molecular Chameleon? , 2006, Cell cycle.
[49] S. Dower,et al. Response of tumour cells to hypoxia: role of p53 and NFkB. , 1998, Molecular pathology : MP.
[50] Thierry Soussi,et al. Shaping genetic alterations in human cancer: the p53 mutation paradigm. , 2007, Cancer cell.
[51] J. Tschopp,et al. Signals from within: the DNA-damage-induced NF-κB response , 2006, Cell Death and Differentiation.
[52] T. Gilmore,et al. Inhibitors of NF-kappaB signaling: 785 and counting. , 2006, Oncogene.
[53] D. Saur,et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA , 2009, Gut.
[54] C. Scheidereit. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. , 2006, Oncogene.
[55] E. Boye,et al. The multiple facets of the intra-S checkpoint , 2008, Cell cycle.
[56] H. Kuo,et al. Involvement of tumor suppressor protein p53 and p38 MAPK in caffeic acid phenethyl ester-induced apoptosis of C6 glioma cells. , 2003, Biochemical pharmacology.
[57] A. Levine. The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. , 2009, Virology.
[58] David A. Williams,et al. TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. , 2007, The Journal of clinical investigation.
[59] N. Perkins,et al. Integrating cell-signalling pathways with NF-κB and IKK function , 2007, Nature Reviews Molecular Cell Biology.
[60] M. Kaufman,et al. High-frequency developmental abnormalities in p53-deficient mice , 1995, Current Biology.
[61] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[62] V. Rotter,et al. Cancer cells suppress p53 in adjacent fibroblasts , 2009, Oncogene.
[63] M. Shiao,et al. Apoptotic effect of caffeic acid phenethyl ester and its ester and amide analogues in human cervical cancer ME180 cells. , 2003, Anticancer research.
[64] K. Kinzler,et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.
[65] B. Aggarwal,et al. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[66] Hong-Hee Kim,et al. Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos. , 2009, International immunopharmacology.
[67] K. Vousden,et al. Role of NF-κB in p53-mediated programmed cell death , 2000, Nature.
[68] L. O’Neill,et al. Diversity and regulation in the NF-κB system , 2007 .
[69] M. Dewhirst,et al. Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. , 2006, Cancer research.
[70] W. Deppert,et al. Transcription-independent pro-apoptotic functions of p53. , 2005, Current opinion in cell biology.
[71] V. Tergaonkar. NFkappaB pathway: a good signaling paradigm and therapeutic target. , 2006, The international journal of biochemistry & cell biology.
[72] R. Stauber,et al. Acetylation of Stat1 modulates NF-B activity , 2006 .
[73] L. Wiesmüller,et al. Identification of a novel pro-apopotic function of NF-κB in the DNA damage response , 2009, Journal of cellular and molecular medicine.
[74] W. El-Deiry,et al. p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. , 1998, Cancer research.
[75] W. El-Deiry,et al. Restoration of p53 to limit tumor growth , 2008, Current opinion in oncology.
[76] T. Gilmore,et al. Inhibitors of NF-κB signaling: 785 and counting , 2006, Oncogene.
[77] H. Wu,et al. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. , 1994, The Journal of biological chemistry.
[78] K. Khalili,et al. Cell cycle regulation of NF-κB-binding activity in cells from human glioblastomas , 2001 .
[79] Somasekar Seshagiri,et al. ATM Engages Autodegradation of the E3 Ubiquitin Ligase COP1 After DNA Damage , 2006, Science.
[80] R. Stauber,et al. A phosphorylation-acetylation switch regulates STAT1 signaling. , 2009, Genes & development.
[81] A. Marusyk,et al. Replicational Stress Selects for p53 Mutation , 2007, Cell cycle.
[82] W. Greene,et al. p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. , 2004, The Journal of biological chemistry.
[83] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[84] R. Poon,et al. Stalled replication induces p53 accumulation through distinct mechanisms from DNA damage checkpoint pathways. , 2006, Cancer research.
[85] F. Shanahan,et al. Targeting the Fas/Fas ligand pathway in cancer , 2005, Expert opinion on therapeutic targets.
[86] Nobuyuki Tanaka,et al. p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation , 2008, Nature Cell Biology.
[87] Y. Ben-Neriah,et al. NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.
[88] M. Kimmel,et al. TNFalpha-induced activation of NFkappaB protects against UV-induced apoptosis specifically in p53-proficient cells. , 2008, Acta biochimica Polonica.
[89] R. Wadgaonkar,et al. CREB-binding Protein Is a Nuclear Integrator of Nuclear Factor-κB and p53 Signaling* , 1999, The Journal of Biological Chemistry.
[90] N. Mukaida,et al. IFN-gamma protects cerulein-induced acute pancreatitis by repressing NF-kappa B activation. , 2007, Journal of immunology.
[91] A. Hoffmann,et al. Immortalized fibroblasts from NF-κB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor α after transformation by v-Ras , 2005, Oncogene.
[92] David A. Williams,et al. TNF-α induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells , 2007 .
[93] N. Perkins,et al. Integrating cell-signalling pathways with NF-kappaB and IKK function. , 2007, Nature reviews. Molecular cell biology.
[94] N. Tanaka,et al. Activated p53 induces NF-kappaB DNA binding but suppresses its transcriptional activation. , 2008, Biochemical and biophysical research communications.
[95] M. Hung,et al. Phosphorylation of CBP by IKKα Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF-κB , 2007 .